Somatrogon (Somatrogon-Ghla) 24 mg/1.2 mL, 60 mg/1.2 mL Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 24 mg/1.2 mL, 60 mg/1.2 mL

Reference Brands: Ngenla (USA)

Category: Critical Care

Somatrogon is a long-acting growth hormone injected once a week for children with growth hormone deficiency, instead of daily injections. It comes in pre-filled pens (24 mg and 60 mg) that need refrigeration. It is made by Pfizer as Ngenla and is a patented innovator product. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Product Description:

Somatrogon is a long-acting recombinant human growth hormone. The protein is human growth hormone fused to three copies of the C-terminal peptide of the human chorionic gonadotropin beta subunit — the same natural sequence that gives hCG its long circulating half-life. The fusion slows renal clearance enough to convert a daily injection into a weekly one, which in paediatric growth hormone deficiency changes roughly 365 injections a year into 52.

It is used for children with growth failure due to inadequate endogenous growth hormone secretion. Efficacy in trials was non-inferior to daily somatropin on annualised height velocity; the case for it rests on adherence rather than superior growth. Injection site reactions are more common than with daily preparations, which is the expected trade-off for the larger weekly dose.

Sourcing notes. A fusion-protein biologic, originator only, on patent. There is no generic route — any follow-on would be a biosimilar with its own comparability and clinical programme, which is not contract manufacturing in the sense buyers usually mean here. Cold chain throughout, 2-8°C, and the weekly dosing schedule makes continuity of supply more important to a paediatric endocrinology service than unit price.